Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Geron Corporation

< Previous 1 2 3 4 Next >
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Tickers GERN
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
From Geron Corporation
Via Business Wire
Tickers GERN
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.